Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis

Setoguchi, Soko, Solomon, Daniel H., Weinblatt, Michael E., Katz, Jeffrey N., Avorn, Jerry, Glynn, Robert J., Cook, E. Francis, Carney, Greg, Schneeweiss, Sebastian·2006·Arthritis & Rheumatism

Abstract

Objective: Concerns persist about a possible association between tumor necrosis factor α (TNFα) antagonist treatment and development of cancers in patients with rheumatoid arthritis (RA). This study was undertaken to estimate the association between treatment with biologic disease‐modifying antirheumatic drugs (DMARDs) and development of cancer in patients with RA. Methods: We conducted a cohort study pooling administrative databases from 2 US states and 1 Canadian province. A cohort of patients who had received a diagnosis of RA on ≥1 occasion and had been prescribed DMARDs was identified. We categorized patients with a prescription for a biologic DMARD as biologic DMARD users, and those with a prescription for methotrexate (MTX) but no biologic DMARD as MTX users. We used time‐varying propensity scores to adjust for the large number of possible confounders and stratified proportional hazards regression to estimate the effects of biologic DMARDs on cancer. The primary end points were hematologic malignancies (lymphoma, multiple myeloma, and leukemia) and common solid tumors (colorectal, lung, stomach, breast, prostate, uterine, ovarian, urinary tract/bladder, and melanoma). Results: The pooled cohort included 1,152 biologic DMARD users and 7,306 MTX users. We identified 11 hematologic malignancies and 46 solid tumors during 2,940 person‐years of biologic DMARD use, and 88 hematologic malignancies and 558 solid tumors during 30,300 person‐years of MTX use. Comparing biologic DMARD users with MTX users, the propensity score–adjusted pooled hazard ratio was 1.37 (95% confidence interval 0.71–2.65) for hematologic malignancies and 0.91 (95% confidence interval 0.65–1.26) for solid tumors. Conclusion: Our results indicate that users of biologic agents are unlikely to have a substantial increase in the risk of hematologic malignancies and solid tumors as compared with MTX users. Despite the use of large combined data sets, studying the effect of an infrequent exposure (biologic DMARDs) on rare diseases (hematologic malignancies) remains a challenge.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.22056

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 240

Metadata

Authors
Setoguchi, S., Solomon, D. H., Weinblatt, M. E., Katz, J. N., Avorn, J., Glynn, R. J., Cook, E. F., Carney, G., & Schneeweiss, S.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2006-08-31
Volume
54
Issue
9
Pages
2757-2764
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2089548173
Cited by
240
References
1
FWCI
14.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.22056
The paper
Setoguchi, S., Solomon, D. H., Weinblatt, M. E., Katz, J. N., Avorn, J., Glynn, R. J., Cook, E. F., Carney, G., & Schneeweiss, S. (2006). Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.22056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.